Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) EBIT: 2018-2019

Historic EBIT for DiaMedica Therapeutics (DMAC) over the last 2 years, with Dec 2019 value amounting to -$2.8 million.

  • DiaMedica Therapeutics' EBIT fell 30.85% to -$2.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$11.6 million, marking a year-over-year decrease of 71.49%. This contributed to the annual value of -$26.7 million for FY2024, which is 25.46% down from last year.
  • Latest data reveals that DiaMedica Therapeutics reported EBIT of -$2.8 million as of Q4 2019, which was down 4.10% from -$2.7 million recorded in Q3 2019.
  • In the past 5 years, DiaMedica Therapeutics' EBIT ranged from a high of -$1.3 million in Q1 2018 and a low of -$3.4 million during Q1 2019.
  • Its 2-year average for EBIT is -$2.3 million, with a median of -$2.4 million in 2018.
  • Data for DiaMedica Therapeutics' EBIT shows a maximum YoY slumped of 161.94% (in 2019) over the last 5 years.
  • Over the past 2 years, DiaMedica Therapeutics' EBIT (Quarterly) stood at -$2.1 million in 2018, then crashed by 30.85% to -$2.8 million in 2019.
  • Its EBIT stands at -$2.8 million for Q4 2019, versus -$2.7 million for Q3 2019 and -$2.7 million for Q2 2019.